Your browser doesn't support javascript.
loading
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Passaro, Antonio; Al Bakir, Maise; Hamilton, Emily G; Diehn, Maximilian; André, Fabrice; Roy-Chowdhuri, Sinchita; Mountzios, Giannis; Wistuba, Ignacio I; Swanton, Charles; Peters, Solange.
Afiliação
  • Passaro A; Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Al Bakir M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
  • Hamilton EG; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Diehn M; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • André F; Gustave-Roussy Cancer Center, Paris Saclay University, Villejuif, France.
  • Roy-Chowdhuri S; Department of Anatomic Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mountzios G; Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
  • Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Oncology, University College London Hospitals, London, UK.
  • Peters S; Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.
Cell ; 187(7): 1617-1635, 2024 Mar 28.
Article em En | MEDLINE | ID: mdl-38552610
ABSTRACT
The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Medicina de Precisão / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Medicina de Precisão / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article